Immunological monitoring of patients with melanoma after peptide vaccination using soluble peptide/hla-a2 dimer complexes

Journal of Immunotherapy

Volumn 27, Issue 1, 2004, Pages 48-59

  Hu, Hong Ming ^a   Dols, Annemieke ^a   Meijer, Sybren L ^a   Floyd, Kevin ^a   Walker, Edwin ^b   Urba, Walter J ^b   Fox, Bernard A ^b  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Dimer; Gp100; Melanoma; Vaccine

Indexed keywords

ADJUVANT; BETA 2 MICROGLOBULIN; CANCER VACCINE; CD8 ANTIGEN; DIMER; FLUORESCENT DYE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN G1; ISOLEUCYLMETHIONYLASPARTYLGLUTAMINYLVALYLPROLYLPHENYLALANYLSERYLVALINE; ISOLEUCYLTHREONYLASPARTYLGLUTAMINYLVALYLPROLYLPHENYLALANYLSERYLVALINE; PEPTIDE DERIVATIVE; TETRAMER; TYROSYLLEUCYLGLUTAMYLPROLYLGLYCYLPROLYLVALYLTHREONYLALANINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CELL ASSAY; CELL LABELING; CELL SPECIFICITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DESIGN; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; EVALUATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOLOGICAL MONITORING; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOID CELL LINE; MELANOMA; MEMORY CELL; MOLECULAR INTERACTION; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; T LYMPHOCYTE ACTIVATION; TECHNIQUE; TITRIMETRY; VACCINATION;

ANIMALS; CANCER VACCINES; CRYOPRESERVATION; DENDRITIC CELLS; DIMERIZATION; HLA-A2 ANTIGEN; HUMANS; INTERLEUKIN-18; MELANOMA; MEMBRANE GLYCOPROTEINS; MONITORING, IMMUNOLOGIC; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; VACCINATION; VACCINES, SUBUNIT;

EID: 0347915732     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200401000-00005     Document Type: Article

References (39)

1. Power CA, Grand CL, Ismail N, et al. A valid ELISPOT assay for enumeration of ex vivo, antigen-specific, IFNgamma-producing T cells. J Immunol Methods. 1999; 227:99.
2. Czerkinsky C, Andersson G, Ekre HP, et al. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods. 1988; 110:29.
3. Badovinac VP, Harty JT. Intracellular staining for TNF and IFN-gamma detects different frequencies of antigen-specific CD8(+) T cells. J Immunol Methods. 2000; 238:107.
4. Maino VC, Picker LJ. Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Cytometry. 1998; 34:207.
5. Brosterhus H, Brings S, Leyendeckers H, et al. Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion. Eur J Immunol. 1999; 29:4053.
6. Janetzki S, Song P, Gupta V, et al. Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma elispot assay. J Immunol Methods. 2000; 234:1.
7. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996; 274:94.
8. Doherty PC. The numbers game for virus-specific CD8+ T cells. Science. 1998; 280:227.
9. McMichael AJ, O'Callaghan CA. A new look at T cells. J Exp Med. 1998; 187:1367.
10. Romero P, Dunbar PR, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med. 1998; 188:1641.
11. Dal Porto J, Johansen TE, Catipovic B, et al. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci U S A. 1993; 90:6671.
12. Schneck JP. Monitoring antigen-specific T cells using MHC-Ig dimers. Immunol Invest. 2000; 29:163.
13. Greten TF, Slansky JE, Kubota R, et al. Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19-specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci U S A. 1998; 95:7568.
14. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319:1676.
15. Ismaili J, Rennesson J, Aksoy E, et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol. 2002; 168:926.
16. Schoenhals GJ, Krishna RM, Grandea 3rd, AG et al. Retention of empty MHC class I molecules by tapasin is essential to reconstitute antigen presentation in invertebrate cells. EMBO J. 1999; 18:743.
17. Cai Z, Brunmark A, Jackson MR, et al. Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells. Proc Natl Acad Sci U S A. 1996; 93:14736.
18. Jackson MR, Song ES, Yang Y, et al. Empty and peptide-containing conformers of class I major histocompatibility complex molecules expressed in Drosophila melanogaster cells. Proc Natl Acad Sci U S A. 1992; 89:12117.
19. Matsumura M, Saito Y, Jackson MR, et al. In vitro peptide binding to soluble empty class I major histocompatibility complex molecules isolated from transfected Drosophila melanogaster cells. J Biol Chem. 1992; 267:23589.
20. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A. 1996; 93:4102.
21. Dutoit V, Rubio-Godoy V, Dietrich PY, et al. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res. 2001; 61:5850.
22. Zeh 3rd, HJ Perry-Lalley D, Dudley ME, et al. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol. 1999; 162:989.
23. Hernandez J, Lee PP, Davis MM, et al. The use of HLA A2. 1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J Immunol. 2000; 164:596-602.
24. Gillespie G, Mutis T, Schrama E, et al. HLA class I-minor histocompatibility antigen tetramers select cytotoxic T cells with high avidity to the natural ligand. Hematol J. 2000; 1:403.
25. Bullock TN, Mullins DW, Colella TA, et al. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice. J Immunol. 2001; 167:5824.
26. Burrows SR, Kienzle N, Winterhalter A, et al. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. J Immunol. 2000; 165:6229.
27. de Visser KE, Cordaro TA, Kioussis D, et al. Tracing and characterization of the low-avidity self-specific T cell repertoire. Eur J Immunol. 2000; 30:1458.
28. Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst. 1998; 90:1894.
29. Valmori D, Dutoit V, Schnuriger V, et al. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol. 2002; 168:4231.
30. Toshitani K, Braud V, Browning MJ, et al. Expression of a single-chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes. Proc Natl Acad Sci U S A. 1996; 93:236.
31. Lee L, Loftus D, Appella E, et al. A recombinant single-chain HLA-A2.1 molecule, with a cis active beta-2-microglobulin domain, is biologically active in peptide binding and antigen presentation. Hum Immunol. 1996; 49:28.
32. Abastado JP, Lone YC, Casrouge A, et al. Dimerization of soluble major histocompatibility complex-peptide complexes is sufficient for activation of T cell hybridoma and induction of unresponsiveness. J Exp Med. 1995; 182:439.
33. McCluskey J, Boyd LF, Highet PF, et al. T cell activation by purified, soluble, class I MHC molecules. Requirement for polyvalency. J Immunol. 1988; 141:1451.
34. Mottez E, Langlade-Demoyen P, Gournier H, et al. Cells expressing a major histocompatibility complex class I molecule with a single covalently bound peptide are highly immunogenic. J Exp Med. 1995; 181: 493.
35. Lone YC, Motta I, Mottez E, et al. In vitro induction of specific cytotoxic T lymphocytes using recombinant single-chain MHC class I/peptide complexes. J Immunother. 1998; 21:283.
36. Corr M, Slanetz AE, Boyd LF, et al. T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science. 1994; 265:946.
37. Greten TF, Korangy F, Neumann G, et al. Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. J Immunol Methods. 2002; 271:125.
38. Lee KH, Wang E, Nielsen MB, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol. 1999; 163:6292.
39. Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998; 188:2205.